CN109415438A - 一类抗cd20靶向抗体及用途技术领域 - Google Patents

一类抗cd20靶向抗体及用途技术领域 Download PDF

Info

Publication number
CN109415438A
CN109415438A CN201680084330.0A CN201680084330A CN109415438A CN 109415438 A CN109415438 A CN 109415438A CN 201680084330 A CN201680084330 A CN 201680084330A CN 109415438 A CN109415438 A CN 109415438A
Authority
CN
China
Prior art keywords
antibody
seq
novel
type
rituximab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680084330.0A
Other languages
English (en)
Inventor
赵磊
张帆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN109415438A publication Critical patent/CN109415438A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

提供了一种兼具I型和II型CD20抗体优势的CD20抗体及其核苷酸和氨基酸序列，能够诱导细胞死亡，可制备抗肿瘤药物。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN201680084330.0A 2016-04-24 2016-06-13 一类抗cd20靶向抗体及用途技术领域 Pending CN109415438A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610257652.2A CN105753986B (zh) 2016-04-24 2016-04-24 一类抗cd20靶向抗体及用途
CN2016102576522 2016-04-24
PCT/CN2016/085531 WO2017185492A1 (zh) 2016-04-24 2016-06-13 一类抗cd20靶向抗体及用途技术领域

Publications (1)

Publication Number Publication Date
CN109415438A true CN109415438A (zh) 2019-03-01

Family

ID=56325626

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610257652.2A Active CN105753986B (zh) 2016-04-24 2016-04-24 一类抗cd20靶向抗体及用途
CN201680084330.0A Pending CN109415438A (zh) 2016-04-24 2016-06-13 一类抗cd20靶向抗体及用途技术领域

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610257652.2A Active CN105753986B (zh) 2016-04-24 2016-04-24 一类抗cd20靶向抗体及用途

Country Status (3)

Country Link
US (1) US20190135934A1 (zh)
CN (2) CN105753986B (zh)
WO (2) WO2017185492A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116640216A (zh) * 2023-07-20 2023-08-25 合源生物科技(天津)有限公司 抗cd19抗体的抗体、抗cd22抗体的抗体及其应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105753986B (zh) * 2016-04-24 2019-12-10 赵磊 一类抗cd20靶向抗体及用途
JP7437511B2 (ja) 2019-12-31 2024-02-22 ナヴロジェン インコーポレイテッド 腫瘍免疫抑制因子に不応性の操作されたモノクローナル抗体の組成物及び使用
IL300314A (en) 2020-10-08 2023-04-01 Affimed Gmbh Coupling materials with triple specificity
IL302412A (en) 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
TW202334221A (zh) 2021-11-03 2023-09-01 德商安富美德有限公司 雙特異性cd16a結合劑

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101821292A (zh) * 2007-09-05 2010-09-01 霍夫曼-拉罗奇有限公司 Ⅰ型和ⅱ型抗-cd20抗体的组合疗法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121971A1 (en) * 2002-12-20 2004-06-24 Gang Chen Therapeutic use of tumor necrosis factor-alpha mutein
CN1316019C (zh) * 2002-12-26 2007-05-16 中国医学科学院中国协和医科大学血液学研究所血液病医院 抗cd20嵌合抗体突变体基因及其应用
ZA200706336B (en) * 2005-02-07 2009-01-28 Genentech Inc CD20 antibody variants and uses thereof
CN102030826B (zh) * 2009-09-25 2014-10-29 上海抗体药物国家工程研究中心有限公司 一种高亲和力的抗cd20单克隆抗体
US10016440B2 (en) * 2010-04-21 2018-07-10 Ventirx Pharmaceuticals, Inc. Methods of enhancing antibody-dependent cellular cytotoxicity
US20140271619A1 (en) * 2013-03-12 2014-09-18 Strategic Diagnostics Inc. Cd20 conformational isomers and methods of using
CN104826110B (zh) * 2015-05-19 2017-09-29 中国人民解放军第二军医大学 新一代多功能抗体纳米团簇的制备及其协同治疗应用
CN105753986B (zh) * 2016-04-24 2019-12-10 赵磊 一类抗cd20靶向抗体及用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101821292A (zh) * 2007-09-05 2010-09-01 霍夫曼-拉罗奇有限公司 Ⅰ型和ⅱ型抗-cd20抗体的组合疗法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FAN ZHANG ET AL.: "Combating rituximab resistance by inducing ceramide/lysosome-involved cell death through initiation of CD20-TNFR1 co-localization", 《ONCOIMMUNOLOGY》 *
李华飞: "Rituximab单点突变体H102YK抗肿瘤作用及机制研究", 《中国优秀博硕士学位论文全文数据库（硕士）医药卫生科技辑》 *
洪海燕等: "人CD20胞外区基因在原核***中的表达", 《免疫学杂志》 *
赵磊: "新型CD20抗体的设计及生物学功能研究", 《中国优秀博硕士学位论文全文数据库（博士）医药卫生科技辑》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116640216A (zh) * 2023-07-20 2023-08-25 合源生物科技(天津)有限公司 抗cd19抗体的抗体、抗cd22抗体的抗体及其应用
CN116640216B (zh) * 2023-07-20 2023-11-10 合源生物科技(天津)有限公司 抗cd19抗体的抗体、抗cd22抗体的抗体及其应用

Also Published As

Publication number Publication date
WO2017185492A1 (zh) 2017-11-02
WO2017185949A1 (zh) 2017-11-02
CN105753986B (zh) 2019-12-10
CN105753986A (zh) 2016-07-13
US20190135934A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
CN109415438A (zh) 一类抗cd20靶向抗体及用途技术领域
US7695716B2 (en) Methods of treating neoplastic, autoimmune and inflammatory diseases
CA2824278C (en) Modulating agonistic tnfr antibodies
CN110088132A (zh) 抗tigit抗体，抗pvrig抗体及其组合
CN104619725B (zh) 抗-dr5家族抗体，双特异性或多价抗-dr5家族抗体及其应用方法
US20220002408A1 (en) Bispecific antibody, preparation method thereof and application thereof
TW202039563A (zh) 嵌合抗原及t細胞受體以及使用方法
WO2011071871A1 (en) Methods for enhancing anti-tumor antibody therapy
BR112020016944A2 (pt) Domínios variáveis de anticorpo que alvejam cd33 e uso dos mesmos
JP2022538733A (ja) 新規抗ｃｄ２５抗体
CN103772504B (zh) 人源化抗表皮生长因子受体抗体及其用途
EP4032539A1 (en) Immunocytokine comprising heterodimeric protein complex based on il-15/il-15r alpha
WO2020038355A1 (zh) Tim-3抗体在制备***的药物中的用途
EP1985633A1 (en) Kit of parts for the treatment of cancer or infectious diseases
KR20220010501A (ko) Gitr에 특이적으로 결합하는 단일클론 항체
CN114075289A (zh) 抗cd73的抗体及其用途
CN105229029A (zh) 结合到cd20和cd95的重组双特异性抗体
CN102030826B (zh) 一种高亲和力的抗cd20单克隆抗体
US9963506B2 (en) Human-mouse chimeric anti-CD147 antibody with non-fucosylated glycosylation
AU2013403112B2 (en) Anti-CD20-Flex bifunctional fusion protein, and preparation method and use thereof
TW202138388A (zh) 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
JP2022506430A (ja) Ｃｄ２０に特異的に結合するモノクローナル抗体
WO2023143478A1 (en) Novel anti-cd4 and anti-pd-l1 bispecific antibodies
TW202409067A (zh) Il-12變體、抗pd1抗體、融合蛋白及其用途
EP4320153A1 (en) Methods for the treatment of anaplastic large cell lymphoma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190301

WD01 Invention patent application deemed withdrawn after publication